Acute Cystitis and Pyelonephritis

References

1) Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103-20.
2) Nicolle LE, Bradley S, Colgan R, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2006;40:643-54.
3) FDA updates warnings for fluoroquinolone antibiotics. U.S. Food & Drug Administration. Released 26 July 2016. Available at:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm513183.htm
4) Dan S, Shah A, Justo JA, et al. Prediction of fluoroquinolone resistance in gram-negative bacteria causing bloodstream infections. Antimicrob Agents Chemother 2016; 60:2265-72.
5) Shah A, Justo JA, Bookstaver PB, et al. Application of fluoroquinolone resistance score in management of complicated urinary tract infections. Antimicrob Agents Chemother 2017; 61: e02313-16.
6) Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010;10:43-50.
7) Veve MP, Wagner JL, Kenny RM, et al. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum beta-lactamase urinary tract infection. Int J Antimicrob Agents 2016;48:56-60.
8) Hayes JE, O’Quinn B, Lu K, et al. Fosfomycin resistance among vancomycin-resistant enterococcal isolates at a tertiary care medical center. Presented at American College of Clinical Pharmacy 2016; Abstract # 176.
9) Hammer KL, Justo J, Bookstaver PB, et al. Differential effect of prior β-lactams and fluoroquinolones on risk of bloodstream infections secondary to Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2017 Jan;87(1):87-91.
10) Augustine M, Testerman TL, Justo J, et al. Clinical risk score for prediction of extended-spectrum beta-lactamase-producing Enterobacteriaceae in bloodstream isolates. Infect Control Hosp Epidemiol 2017; 38: 266-272.
11) Pichichero ME. Cephalosporins can be prescribed safely for penicillin-allergic patients. J Fam Pract 2006;55:106-12
12) Jeffres MN, Narayanan PP, Shuster JE, Schramm GE. Consequences of avoiding β-lactams in patients with β-lactam allergies. J Allergy Clin Immunol 2016;137:1148-53.
13) Hoang P, Salbu RL. Updated nitrofurantoin recommendations in the elderly: a closer look at the evidence. Consult Pharm 2016 Jul;31:381-4.
14) Nelson AN, Justo JA, Bookstaver PB, et al. Optimal duration of antimicrobial therapy for uncomplicated gram-negative bloodstream infections. Infection 2017; 45: 613-20.
15) Kutob LF, Justo JA, Bookstaver PB, et al. Effectiveness of oral antibiotics for definitive therapy of gram-negative bloodstream infections. Int J Antimicrob Agents 2016; 48: 498-503.

1) Gupta K, Hooten TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103-20.
2) Nicolle LE, Bradley S, Colgan R, et al. Infectious Diseases Society of America Guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2006;40:643-54.
3) FDA updates warnings for fluoroquinolone antibiotics. U.S. Food & Drug Administration. Released 26 July 2016. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm513183.htm
4) Pichichero ME. Cephalosporins can be prescribed safely for penicillin-allergic patients. J Fam Pract 2006;55:106-12.
5) Shah A, Justo JA, Bookstaver PB, et al. Application of fluoroquinolone resistance score in management of complicated urinary tract infections. Antimicrob Agents Chemother 2017; 61: e02313-16.
6) Falagas ME, et al. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010;10:43-50.
7) Veve MP, et al. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum beta-lactamase urinary tract infection. Int J Antimicrob Agents 2016;48:56-60.
8) Sanasi-Bhola K, et al. Fosfomycin in vitro activity against extended spectrum beta-lactamase positive and carbapenem resistant Enterobacteriaceae urine isolates. Presented at IDWeek 2014. Abstract #40851.
9) Hayes JE, O’Quinn B, Lu K, et al. Fosfomycin resistance among vancomycin-resistant enterococcal isolates at a tertiary care medical center. Presented at American College of Clinical Pharmacy; 2016; Abstract #176.
10) Hoang P, Salbu RL. Updated nitrofurantoin recommendations in the elderly: a closer look at the evidence. Consult Pharm 2016 Jul;31:381-4.